Table 1 Characteristics of the study cohort on admission to the ICU stratified according to whether or not oliguria was present
All patients n = 8292 | Oliguria at admission | p value | ||
|---|---|---|---|---|
No n = 6242 (75.3%) | Yes n = 2050 (24.7) | |||
Urine output (ml/kg/h) median [IQR] | 0.9 [0.5–1.4] | 1.1 [0.8–1.6] | 0.3 [0.1–0.4] | < 0.001 |
Age, years, mean ± SD | 59.2 ± 18.2 | 58.1 ± 18.3 | 62.5 ± 17.4 | < 0.001 |
Male, n (%) | 4928 (60.0) | 3724 (60.2) | 1204 (59.4) | 0.55 |
Severity scores, mean ± SD | ||||
SAPS II score | 40.8 ± 17.5 | 37.9 ± 15.1 | 49.8 ± 20.8 | < 0.001 |
SOFA score at admission | 6.2 ± 4.2 | 5.7 ± 3.8 | 7.6 ± 5.0 | < 0.001 |
SOFA score at admission (without renal subscore) | 5.3 ± 3.7 | 5.1 ± 3.5 | 5.8 ± 4.2 | < 0.001 |
Type of admission, n (%) | ||||
Surgical (non-trauma) | 2939 (37.2) | 2374 (39.9) | 565 (29.2) | < 0.001 |
Medical | 4335 (54.9) | 3063 (51.4) | 1272 (65.7) | |
Trauma | 569 (7.2) | 478 (8.0) | 91 (4.7) | |
Other | 48 (.6) | 40 (.7) | 8 (.4) | |
Source of admission, n (%) | ||||
Other hospital | 825 (9.9) | 625 (10.0) | 200 (9.8) | < 0.01 |
ER/ambulance | 3151 (38.0) | 2336 (37.4) | 815 (39.8) | |
OR/recovery room | 1569 (18.9) | 1304 (20.9) | 265 (12.9) | |
Hospital floor | 2117 (25.5) | 1529 (24.5) | 588 (28.7) | |
Other | 630 (7.6) | 448 (7.2) | 182 (8.9) | |
Comorbidities, n (%) | ||||
COPD | 1012 (12.2) | 737 (11.8) | 275 (13.4) | 0.06 |
Cancer | 891 (10.7) | 684 (11.0) | 207 (10.1) | 0.29 |
Metastatic cancer | 288 (3.5) | 205 (3.3) | 83 (4.0) | 0.11 |
Hematologic cancer | 178 (2.1) | 126 (2.0) | 52 (2.5) | 0.16 |
Insulin | 682 (8.2) | 496 (7.9) | 186 (9.1) | 0.12 |
Heart failure, NYHA III/IV | 648 (7.8) | 445 (7.1) | 203 (9.9) | < 0.001 |
HIV infection | 56 (.7) | 33 (.5) | 23 (1.1) | < 0.01 |
Cirrhosis | 283 (3.4) | 188 (3.0) | 95 (4.6) | < 0.001 |
Immunosuppression | 259 (3.1) | 184 (2.9) | 75 (3.7) | 0.11 |
Steroid therapy | 273 (3.3) | 208 (3.3) | 65 (3.2) | 0.78 |
Chemotherapy | 239 (2.9) | 181 (2.9) | 58 (2.8) | 0.94 |
Organ support, n (%) | ||||
Mechanical ventilation | 4227 (51.0) | 3184 (51.0) | 1043 (50.9) | 0.92 |
Renal replacement therapy | 321 (3.9) | 97 (1.6) | 224 (10.9) | < 0.001 |
Vasopressor use | 2429 (29.3) | 1672 (26.8) | 757 (36.9) | < 0.001 |
Type of organ failure, n (%) (alone or in combination) | ||||
Respiratory | 1867 (22.5) | 1334 (21.4) | 533 (26.0) | < 0.001 |
Coagulation | 530 (6.4) | 345 (5.5) | 185 (9.0) | < 0.001 |
Hepatic | 885 (10.7) | 658 (10.5) | 227 (11.1) | 0.51 |
CNS | 1972 (23.8) | 1435 (23.0) | 537 (26.2) | < 0.01 |
Renal | 1341 (16.2) | 524 (8.4) | 817 (39.9) | < 0.001 |
Cardiovascular | 2296 (27.7) | 1580 (25.3) | 716 (34.9) | < 0.001 |
Number of organ failures, n (%) | ||||
None | 1771 (21.4) | 1489 (23.9) | 282 (13.8) | < 0.001 |
1 organ | 2344 (28.3) | 1805 (28.9) | 539 (26.3) | |
2 organs | 1693 (20.4) | 1302 (20.9) | 391 (19.1) | |
3 organs | 1231 (14.8) | 883 (14.1) | 348 (17.0) | |
> 3 organs | 1253 (15.1) | 763 (12.2) | 490 (23.9) | |
Sepsis, n (%) | 1543 (18.6) | 1041 (16.7) | 502 (24.5) | < 0.001 |
ICU stay, median [IQR] | 3.0 [2.0–6.0] | 3.0 [2.0–6.0] | 3.0 [1.0–7.0] | < 0.001 |
In survivors | 3.0 [1.0–6.0] | 3.0 [1.0–6.0] | 3.0 [0.0–7.0] | 0.046 |
In non-survivors | 3.0 [0.0–8.0] | 5.0 [1.0–10.0] | 2.0 [0.0–6.0] | < 0.001 |
Hospital stay, median [IQR] | 10.0 [5.0–20.0] | 10.0 [6.0–20.0] | 8.0 [2.0–18.0] | < 0.001 |
In survivors | 11.0 [2.0–21.0] | 11.0 [2.0–21.0] | 11.0 [1.0–22.0] | 0.075 |
In non-survivors | 5.0 [0.0–14.0] | 7.0 [1.0–15.0] | 3.0 [0.0–10.0] | < 0.001 |
ICU mortality, n (%) | 1234 (15.2) | 700 (11.5) | 534 (26.8) | < 0.001 |
Hospital mortality, n (%) | 1649 (21.1) | 983 (16.7) | 666 (34.5) | < 0.001 |